Actithera key facts
as of Oct 2026- Operator of a molecular radio therapeutic company intended for biotechnology research services.
- Actithera is valued at approximately $110.0M as of Oct 2026 (last reported valuation).
- It has raised $80.8M; the latest was Early Stage VC ($75.5M) in Jul 2025.
- Notable investors include Sofinnova Partners, Innovestor, M Ventures, Arkin Capital, Surveyor Capital — 10 tracked in total.
- Status: Privately Held (backing).
Actithera's last reported valuation, Jul 2025. Nothing priced has surfaced since.
- ·Watch Actithera: the Monday email on marks, rounds and moves
Actithera funding rounds
No funding rounds for Actithera are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Actithera valuation
Actithera's last reported valuation was $110 million in Jul 2025. No priced round, secondary trade or fund mark has surfaced since.
Actithera investors
10 investors are on record for Actithera, including Sofinnova Partners, Innovestor, M Ventures and Arkin Capital. By type, the record holds 4 venture capital firms, 1 family office and 1 hedge fund.
About Actithera
Operator of a molecular radio therapeutic company intended for biotechnology research services. The company focuses on improving cancer treatment through utilizing radioactive isotopes linked to specific molecules, aiming for precise delivery of radiation directly to cancer cells with an aim to develop radiopharmaceuticals, enabling consumers to get focused radiation for cancer cells while minimizing harm to healthy tissues.
- Sector
- Healthcare
- HQ
- Cambridge, MA, United States
- Founded
- 2021
- Employees
- 3
- Website
- actithera.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.